One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease trio

[Aretaeus Cappadocia]

"Fourteen months after treatment with engineered immune cells, the recipient has no symptoms and doesn’t need to take medication."

Woman had 3 autoimmune diseases that attacked different types of blood cells: autoimmune haemolytic anaemia, immune thrombocytopenia, and antiphospholipid syndrome. Her situation was desperate and likely would have been lethal.

She was treated with CAR-T therapy, which is something of a nuclear attack on the immune system. Not too long ago there was another discussion on this site about this therapy (I looked for it but didn't find it).

Article discusses the suffering she went through, the significant risk to her life, and the miraculous cure (or remission at least). Article does not discuss any of the downsides of the therapy so it's harder to assess whether this is a story about a successful, one-off hail mary, or if it is something that might be more widely applicable in less lethal autoimmune diseases.

https://www.nature.com/articles/d41586-026-01108-4

[Scott Adams]

Thanks for sharing this. The Nature article you linked confirms your key points: this 47-year-old woman’s situation was indeed desperate and life-threatening, requiring daily blood transfusions and failing nine prior treatments, making CAR-T therapy a true "last chance." You are right to note the article does not detail the therapy's downsides—such as the immediate risks from the accompanying chemotherapy, the potential for severe cytokine-release syndrome, or long-term vulnerability to infections due to prolonged B-cell depletion—which makes it harder to generalize from this single, spectacular success. However, the article does hint at broader applicability: the therapy worked by eliminating her rogue B cells, the root cause of all three antibody-driven autoimmune diseases. While this "nuclear attack" carries significant risks, for patients with less lethal but still debilitating autoimmune diseases driven by similar mechanisms, this case provides a powerful proof-of-principle. Whether it becomes a wider treatment option will depend on future trials carefully balancing the therapy's potential for a medication-free remission against its substantial safety risks.

PS - This made me recall this old article: